Find the biotech companies that need capital before their next readout.
TrialCarta Pro reads ClinicalTrials.gov, SEC EDGAR and PubMed together and ranks drug developers with a readout coming and cash that may not last until then, listed and private. Royalty, credit and business development teams see the next deals before they come to market.
Financing Screen analytics from a live run on public data, company names left out.
What it does
Financing Screen
A ranked list of drug developers with a phase 2 or 3 readout in the window you choose: readout timing, cash, runway, and whether the cash lasts to the readout. Analytics, CSV and a PDF brochure to share.
Private companies too
Sponsors that aren't listed don't publish financial statements. TrialCarta shows what SEC filings say about how they're funded and when they last raised.
New companies, on your radar
Sponsors whose first trials were just posted, how they're funded and what's published on the drug. Keep the ones you like on your radar and hear when they move.
Alerts every week
Watched screens and companies are re-checked weekly: new raises, readouts that moved, trials stopped or completed, results posted, going-concern wording and royalty deals signed.
Deal terms from filings
Search EDGAR for licensing, royalty and financing agreements and see the upfront, milestone and royalty terms quoted from the filing itself.
A brief on any company
Ask for a financing brief: the lead asset's evidence, the readout ahead, runway and obligations. Every figure cites its filing or trial record, and citations are checked before you see them.
Why you can rely on it
- Public sources, read fresh. ClinicalTrials.gov, SEC EDGAR (filings, reported financials and private-placement notices) and PubMed, retrieved each time you run it. Every number links back to where it came from.
- Tested on history. Run as of mid-2021 and early 2023, the ranking put two to three times more of the companies that went on to sell a royalty in its top ten than a random pick would.
- Rules for the numbers, AI for the reading. Cash, runway and rankings come from fixed rules you can check. The AI model writes briefs from the records, and every citation is verified against them.
- Your deal work stays with you. TrialCarta runs on your Mac, AI model included. Only the public searches go out; your documents, questions and notes never leave the computer.
Built for
Royalty and structured finance
Source companies with strong evidence and a funding need ahead of the readout.
Venture debt and credit
See runway against milestones, and hear when a borrower raises or a trial slips.
Biotech investors
Track readouts, financings and new private companies across a whole indication.
Pharma BD and licensing
Spot partners that may want a deal before their data, and read the terms of comparable deals.
How it's licensed
TrialCarta Pro is an add-on to a TrialCarta license, for one person or a team, priced per person per year. Enterprise licenses include it. TrialCarta runs on a Mac, and a trial copy includes everything in Pro so you can try it on your own questions.
Figures come from public data and are approximate. TrialCarta is a screening and research aid, not investment advice: check figures against the filings before relying on them.
Common questions
Where does the data come from?
Public sources only: ClinicalTrials.gov, SEC EDGAR (filings, reported financials and private-placement notices) and PubMed, read fresh each time you run it.
Do our deal documents leave our office?
No. TrialCarta runs on your Mac, including the AI model. Only the public searches go out; your documents, questions and notes stay on the computer.
Does it cover companies outside the US?
Their trials, yes. Financial figures come from SEC filings, so cash and runway cover companies listed in the US, and private funding covers US private raises.
Can we try it?
Yes. Ask for a demo on this week's data, or for a sample brochure, and we'll send a trial copy.
See it on this week's data
We'll run the Financing Screen live, walk through a company brief, and show the alerts and radar.
Ask for a demo